Evidence map›Paper›PMID 32577417›Full record

ArticleERJ open research2020

Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA.

Pailin Ratanawatkul, Joshua J Solomon, Darlene Kim, Marjorie P George, Lia R Matarrese McGibbon, M Kristen Demoruelle, Mehrnaz Maleki-Fischbach, Isabelle Amigues, Liudmila Kastsianok, Evans R Fernández Pérez

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Observational
  3. Secular Trends in Systemic Sclerosis Mortality in the United States from 1981 to 2020.International journal of environmental research and public health · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Pailin RatanawatkulDivision of Pulmonary and Critical Care Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.ORCID https://orcid.org/0000-0003-2763-2158
Joshua J SolomonDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
Darlene KimDivision of Cardiology, National Jewish Health, Denver, CO, USA.
Marjorie P GeorgeDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
Lia R Matarrese McGibbonDivision of Rheumatology, National Jewish Health, Denver, CO, USA.
M Kristen DemoruelleDivision of Rheumatology, National Jewish Health, Denver, CO, USA.
Mehrnaz Maleki-FischbachDivision of Rheumatology, National Jewish Health, Denver, CO, USA.
Isabelle AmiguesDivision of Rheumatology, National Jewish Health, Denver, CO, USA.
Liudmila KastsianokDivision of Rheumatology, National Jewish Health, Denver, CO, USA.
Evans R Fernández PérezDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.ORCID https://orcid.org/0000-0001-7535-1591
National Jewish Health · USKhon Kaen University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are limited data nationwide on the burden of systemic sclerosis (SSc)-related mortality. We aimed to determine recent trends in SSc and SSc-related pulmonary arterial hypertension (PAH) mortality overall and across population subgroups. Using death certificate data from the National Center for Health Statistics, we computed the age-adjusted mortality rates of SSc and SSc-SSc-PAH, a lethal prevailing complication, across demographic groups, geographic regions and comorbid cardiorespiratory conditions, and used Joinpoint regression analysis to calculate the average annual percentage change (APC) in mortality. From 2003 to 2016, 25 175 death records contained a code for SSc. Decedents were predominantly female (81%) and white (73%), with an average age of 66±14 years. The age-adjusted mortality rate decreased by 3% per year from 6.6 in 2003 to 4.3 per 1 000 000 population in 2016. Also, a decreasing trend was found when SSc was stratified by age, sex, race and geographic region. The prevalence of PAH was 23%. The odds of PAH were highest in female and black decedents, and in decedents with concomitant pulmonary embolism, cardiomyopathy and interstitial lung disease (ILD). SSc-PAH mortality remained stable from 2003 to 2008 then decreased by 3% per year from 2008 to 2016. In decedents with SSc-PAH, among all concomitant comorbidities, the mortality rate associated with ILD had the highest increase (average APC 6%, 95% CI 2%-10%). The mortality rate from SSc decreased from 2003 to 2016. Decreases in mortality rates were similar across demographic groups and geographic regions. SSc-PAH-related mortality remained stable. The death rate for SSc-ILD and concomitant PAH increased during this period.

Identifiers

PMID32577417
PMCPMC7293989
OpenAlexW3035640841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.